NCT06453044View on ClinicalTrials.gov

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

March 14, 2028

Study Completion Date

March 14, 2028

Conditions
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Mosunetuzumab

Given SC

DRUG

Polatuzumab Vedotin

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary Studies

Trial Locations (2)

91010

RECRUITING

City of Hope Medical Center, Duarte

92618

NOT_YET_RECRUITING

City of Hope Orange County Lennar Foundation Cancer Center, Irvine

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER